Nephrology Times
Advertisement
Drs. Cynthia Delgado and Neil R. Powe made TIME's list of the 100 most influential people in global health.
In kidney and liver transplant recipients, steroids and mycophenolic acid were associated with COVID-19 hospitalization risk.
Higher dialysate sodium preserves blood volume and hemodynamic stability but reduces sodium removal.
A study reported on dual-drug resistance in a kidney transplant patient who received sotrovimab and remdesivir for COVID-19.
Nephrology Times will cover the National Kidney Foundation Spring Clinical Meetings 2024 live and onsite.
The National Kidney Foundation will honor distinguished health care professionals at the 2024 Spring Clinical Meetings.
Researchers studied the effect of intensive blood pressure control on the progression of IgAN.
Researchers explored the association between CSVD and CKD plus the potential role of hypertension in this association.
With four acquisitions from Fresneius Medical Care, DaVita will become the largest dialysis provider in Latin America.
Researchers examined use of clinical decision support systems to decrease blood pressure in hypertensive patients with CKD.
The FDA gave Breakthrough Device designation to the JuxtaFlow RAD to help prevent AKI during cardiothoracic surgery.
Accurate prediction of severe outcomes of acute kidney injury remains challenging.
FILSPARI (sparsentan) has received conditional marketing authorization from the European Commission to treat IgAN in adults.
Researchers examined the roles of hyperuricemia and anemia in all-cause mortality with chronic kidney disease (CKD).
Outset Medical and US Renal Care have partnered to advance home dialysis with the Outset Tablo Hemodialysis System.
A New Jersey woman with heart and kidney failure received a genetically engineered pig kidney and a mechanical heart pump.
The ERA reviewed phase 3 trials to clarify the mechanism behind HIF-PHi and their role in managing CKD-related anemia.
A bill to improve access to care and outcomes for some dialysis patients was introduced in the House of Representatives.
Research has begun to question recommendations to restrict potassium with CKD to manage hyperkalemia.
Will sparsentan prove a winner for patients with FSGS, or are we doomed to forever treat them with Acthar Gel?
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.